首页> 美国卫生研究院文献>Cancer Medicine >Chemokines and chemokine receptors: A new strategy for breast cancer therapy
【2h】

Chemokines and chemokine receptors: A new strategy for breast cancer therapy

机译:趋化因子和趋化因子受体:乳腺癌治疗的新策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chemokines and chemokine receptors not only participate in the development of tissue differentiation, hematopoiesis, inflammation, and immune regulation but also play an important role in the process of tumor development. The role of chemokines and chemokine receptors in tumors has been emphasized in recent years. More and more studies have shown that chemokines and chemokine receptors are closely related to the occurrence, angiogenesis, metastasis, drug resistance, and immunity of breast cancer. Here, we review recent progression on the roles of chemokines and chemokine receptors in breast cancer, and discuss the possible mechanism in breast cancer that might facilitate the development of new therapies by targeting chemokines as well as chemokine receptors. Chemokines and chemokine receptors play an important role in the occurrence and development of breast cancer. In‐depth study of chemokines and chemokine receptors can provide intervention targets for breast cancer biotherapy. The regulation of chemokines and chemokine receptors may become a new strategy for breast cancer therapy.
机译:趋化因子和趋化因子受体不仅参与组织分化,造血,炎症和免疫调节的发展,而且在肿瘤发展过程中起重要作用。近年来,已经强调了趋化因子和趋化因子受体在肿瘤中的作用。越来越多的研究表明趋化因子和趋化因子受体与乳腺癌的发生,血管生成,转移,耐药性和免疫力密切相关。在这里,我们回顾了趋化因子和趋化因子受体在乳腺癌中的作用的最新进展,并讨论了乳腺癌中可能的机制,该机制可能通过靶向趋化因子以及趋化因子受体来促进新疗法的发展。趋化因子和趋化因子受体在乳腺癌的发生和发展中起重要作用。对趋化因子和趋化因子受体的深入研究可以为乳腺癌生物疗法提供干预目标。趋化因子和趋化因子受体的调节可能成为乳腺癌治疗的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号